EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

ErbB signaling is a potential therapeutic target for vascular lesions with fibrous component

Suvi Jauhiainen iD, Henna Ilmonen, Pia Vuola, Heta Rasinkangas, Heidi H Pulkkinen, Sara Keränen, Miika Kiema iD, Jade J Liikkanen, Nihay Laham-Karam iD, Svetlana Laidinen, Mustafa Beter, Einari Aavik iD und 9 weitere

eLife · 18.05.2023 · 12

DOI: 10.7554/elife.82543 ↗

Kurz gefasst

Fachartikel in der Zeitschrift eLife, online erschienen am 18.05.2023. Verfasst von Suvi Jauhiainen und 20 weiteren Autor:innen. Beteiligte Einrichtung: A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland. Hauptthemen laut MEDLINE: Endothelial Cells, Vascular Malformations. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Academy of Finland, Ella and Georg Ehnrooth Foundation, CoE of Cardiovascular and Metabolic Disease.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Sporadic venous malformation (VM) and angiomatosis of soft tissue (AST) are benign, congenital vascular anomalies affecting venous vasculature. Depending on the size and location of the lesion, symptoms vary from motility disturbances to pain and disfigurement. Due to the high recurrence of the lesions, more effective therapies are needed.

Methods

As targeting stromal cells has been an emerging concept in anti-angiogenic therapies, here, by using VM/AST patient samples, RNA-sequencing, cell culture techniques, and a xenograft mouse model, we investigated the crosstalk of endothelial cells (EC) and fibroblasts and its effect on vascular lesion growth.

Results

We report, for the first time, the expression and secretion of transforming growth factor A (TGFA) in ECs or intervascular stromal cells in AST and VM lesions. TGFA induced secretion of vascular endothelial growth factor (VEGF-A) in paracrine fashion, and regulated EC proliferation. Oncogenic PIK3CA variant in p.H1047R, a common somatic mutation found in these lesions, increased TGFA expression, enrichment of hallmark hypoxia, and in a mouse xenograft model, lesion size, and vascularization. Treatment with afatinib, a pan-ErbB tyrosine-kinase inhibitor, decreased vascularization and lesion size in a mouse xenograft model with ECs expressing oncogenic PIK3CA p.H1047R variant and fibroblasts.

Conclusions

Based on the data, we suggest that targeting of both intervascular stromal cells and ECs is a potential treatment strategy for vascular lesions having a fibrous component. Funding: Academy of Finland, Ella and Georg Ehnrooth foundation, the ERC grants, Sigrid Jusélius Foundation, Finnish Foundation for Cardiovascular Research, Jane and Aatos Erkko Foundation, GeneCellNano Flagship program, and Department of Musculoskeletal and Plastic Surgery, Helsinki University Hospital.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Endothelial CellsVascular MalformationsHumansMiceAnimalsVascular Endothelial Growth Factor ASignal TransductionProtein Kinase InhibitorsClass I Phosphatidylinositol 3-Kinases

Stichwörter der Autor:innen

PIK3CA p.H1047RTGFAafatinibangiomatosis of soft tissuecell biologyfibroblastshumanmedicinemousestromal cellsvenous malformation

Substanzen

Vascular Endothelial Growth Factor AProtein Kinase InhibitorsClass I Phosphatidylinositol 3-Kinases

Autor:innen und Institutionen

  • A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland.
  • Department of Plastic Surgery, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
  • VASCERN VASCA European Reference Centre, Helsinki University Hospital, Helsinki, Finland.
  • Department of Radiology, HUS Diagnostic Center and Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
  • Department of Pathology, HUSLAB, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
  • Department of Pediatric Surgery, New Children's Hospital, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.

ORCID-Profile: Suvi Jauhiainen, Miika Kiema, Nihay Laham-Karam, Einari Aavik, Minna U Kaikkonen, Seppo Ylä-Herttuala, Johanna P Laakkonen

Förderung

  • Academy of Finland
  • Ella and Georg Ehnrooth Foundation
  • CoE of Cardiovascular and Metabolic Disease
  • GeneCellNano Flagship Program
  • European Research Council
  • Sigrid Jusélius Foundation
  • Finnish Foundation for Cardiovascular Research
  • Jane and Aatos Erkko Foundation

Zitieren

APA

Jauhiainen, S., Ilmonen, H., Vuola, P., Rasinkangas, H., Pulkkinen, H. H., Keränen, S., Kiema, M., Liikkanen, J. J., Laham-Karam, N., Laidinen, S., Beter, M., Aavik, E., Lappalainen, K., Lohi, J., Aronniemi, J., Örd, T., Kaikkonen, M. U., Salminen, P., Tukiainen, E., …, & Laakkonen, J. P. (2023). ErbB signaling is a potential therapeutic target for vascular lesions with fibrous component. eLife, 12. https://doi.org/10.7554/elife.82543

Vancouver

Jauhiainen S, Ilmonen H, Vuola P, Rasinkangas H, Pulkkinen HH, Keränen S, et al. ErbB signaling is a potential therapeutic target for vascular lesions with fibrous component. eLife. 2023;12. doi:10.7554/elife.82543

BibTeX
@article{Jauhiainen2023,
  author = {Jauhiainen, Suvi and Ilmonen, Henna and Vuola, Pia and Rasinkangas, Heta and Pulkkinen, Heidi H and Keränen, Sara and Kiema, Miika and Liikkanen, Jade J and Laham-Karam, Nihay and Laidinen, Svetlana and Beter, Mustafa and Aavik, Einari and Lappalainen, Kimmo and Lohi, Jouko and Aronniemi, Johanna and Örd, Tiit and Kaikkonen, Minna U and Salminen, Päivi and Tukiainen, Erkki and Ylä-Herttuala, Seppo and Laakkonen, Johanna P},
  title = {ErbB signaling is a potential therapeutic target for vascular lesions with fibrous component},
  journal = {eLife},
  year = {2023},
  volume = {12},
  doi = {10.7554/elife.82543}
}
Kostenlos starten →